James Molloy
Alliance Global Partners
Jim Molloy was a managing director and healthcare equity analyst at Laidlaw Capital Markets. Prior to Laidlaw, Molloy was a managing director at Summer Street Research Partners and Janney Montgomery Scott; prior to that he was a senior analyst at ThinkEquity Partners, Caris & Company, Oppenheimer, and Leerink Swann & Company. Molloy has been ranked by Forbes/Starmine for earnings accuracy. He received his master’s degree in business administration from the FW Olin Graduate School of Business at Babson College, and his bacherlor’s degree from the University of Colorado, Boulder.
Recent Articles
New Drug for Duchenne Muscular Dystrophy Nears Potential Approval 10/06/2025
Capricor Therapeutics Inc. (CAPR:NASDAQ) could receive a PDUFA date for its cell therapy as early as spring 2026 if it follows the FDA-outlined path forward, noted an Alliance Global Partners report.
Recent Quotes
"We continue to believe that, should Posimir read out positively and DUR-928 get out of Phase 1 trials, DRRX is an undervalued story here."
—
James Molloy, Laidlaw & Company
(3/15/17)
more >
